Texas' top court nixes $32M Vioxx award

Merck ($MRK) won a reversal of the $32 million jury verdict in a Texas case over the Vioxx painkiller. The state's Supreme Court decided that the family of Leonel Garza didn't produce enough evidence to show Vioxx caused his heart attack, thus tossing out the 2006 verdict. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.